Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + FLAI in New Onset Non-M3 Acute Myeloid Leukemia
NCT03455504Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Oct 2018
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax in acute myeloid leukemia (AML) (2 cohorts), sponsored by GIMEMA. Primary endpoint: Complete Response at 24 months. Started Oct 2018; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03455504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03455504.